Details for Patent: 5,880,106

Summary for Patent: 5,880,106

Title:	Oral dosing formulations of dideoxy purine nucleosides
Abstract:	Improved oral dosage formulations for acid-labile dideoxy purine nucleoside derivatives such as ddA, ddI, and ddG, have been developed by incorporating selected water-insoluble buffering systems in the formulation. These novel formulations provide reduced mass dosage units in the form of convenient, palatable chewable/dispersible tablets or a dry powder sachet. The reduced mass requirement, necessary to allow tablets of reasonable size, was achieved in part by an unexpected 20 to 25% increase in drug bioavailability resulting from use of the selected buffering systems comprised of an insoluble magnesium antacid agent and either dihydroxyaluminum sodium carbonate or calcium carbonate.
Inventor(s):	Ullah; Ismat (Cranbury, NJ), Agharkar; Shreeram Narahari (Princeton, NJ), Wiley; Gary James (Jackson, NJ)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	08/942,660
Patent Claim Types: see list of patent claims	Composition; Delivery; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 5,880,106

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 5,880,106

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	163855
Australia	2039692
Australia	657337
Canada	2074215